I. Wauters

发表

Erythropoiesis-stimulating agents in cancer patients: reflections on safety

I. Wauters, J. Vansteenkiste, 2011, Expert review of clinical pharmacology.

Chemotherapy-induced anemia: the story of darbepoetin alfa

J. Vansteenkiste, S. Elliott, J. Glaspy, 2013, Current medical research and opinion.

Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy

I. Wauters, J. Vansteenkiste, 2012, Expert review of anticancer therapy.

Darbepoetin alfa in the treatment of chemotherapy-induced anaemia

I. Wauters, J. Vansteenkiste, Isabelle Wauters, 2009 .

Quality of care and variability in lung cancer management across Belgian hospitals: a population-based study using routinely available data

J. V. van Meerbeeck, S. Stordeur, E. van Eycken, 2018, International journal for quality in health care : journal of the International Society for Quality in Health Care.

LUNG CANCER GUIDELINES EXPERT PANEL

P. Houtte, B. Weynand, P. Pauwels, 2013 .

Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development.

J. Vansteenkiste, I. Wauters, L. Decoster, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases

I. Wauters, J. Dupont, E. Gielen, 2022, Bone reports.

The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia

J. Vansteenkiste, I. Wauters, 2005, Expert opinion on pharmacotherapy.

Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia

I. Wauters, J. Vansteenkiste, K. Pat, 2006, Therapeutics and clinical risk management.

Darbepoetin alfa for chemotherapy-induced anemia: evolution to extended dosing intervals

J. Vansteenkiste, I. Wauters, 2007, Expert review of anticancer therapy.

Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer

I. Wauters, J. Vansteenkiste, V. Adam, 2014, Expert opinion on biological therapy.

Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma

E. Wauters, S. Ocak, T. Vander Borght, 2022, Frontiers in Oncology.

Performance of standard procedures in detection of EGFR mutations in daily practice in advanced NSCLC patients selected according to the ESMO guideline: a large Caucasian cohort study

C. Dooms, K. Nackaerts, T. Roskams, 2014, Translational Respiratory Medicine.

Maintenance therapy for advanced non-small-cell lung cancer: ready for clinical practice?

J. Vansteenkiste, I. Wauters, A. Sibille, 2012, Expert review of anticancer therapy.

Immunotherapy for non-small-cell lung cancer: the past 10 years.

N. De Brucker, I. Wauters, J. Vansteenkiste, 2015, Future oncology.

Darbepoetin alfa in the treatment of chemotherapy-induced anaemia.

I. Wauters, J. Vansteenkiste, 2009, Expert Opinion on Biological Therapy.

Maintenance Therapy for Advanced Non–Small-Cell Lung Cancer: A Pilot Study on Patients’ Perceptions

C. Dooms, K. Nackaerts, J. Vansteenkiste, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical factors predictive of long-term survival in advanced non-small cell lung cancer.

C. Dooms, K. Nackaerts, J. Vansteenkiste, 2013, Lung cancer.

Association between surgical volume and post-operative mortality and survival after surgical resection in lung cancer in Belgium: A population-based study.

G. Silversmit, J. V. van Meerbeeck, S. Stordeur, 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Observational Aranesp® Survey to Investigate the Q3W Schedule (OASIS): a prospective observational study of treatment of chemotherapy-induced anaemia with every 3 weeks darbepoetin alfa

M. Derde, M. Polus, I. Wauters, 2009, Supportive Care in Cancer.

Patterns of care for non‐small cell lung cancer patients in Belgium: A population‐based study

G. Silversmit, J. V. van Meerbeeck, S. Stordeur, 2018, European journal of cancer care.

The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective database.

C. Dooms, K. Nackaerts, B. Weynand, 2016, Lung cancer.

Melanoma-associated antigen-A3 vaccination in the treatment of non-small-cell lung cancer

I. Wauters, J. Vansteenkiste, V. Adam, 2014, Expert opinion on biological therapy.